An observational study in Type 1 Diabetes, sponsored by Sanofi. Recruiting at 12 sites in 4 countries. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 66th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Sanofi · Sites in Kuwait, Saudi Arabia, United Arab Emirates
Ages 18 mo–18 yrs · Healthy volunteers
Sanofi · Sites in United States
Ages 8+
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Sanofi · Sites in United States
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 6 · Phase 3 20 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 86 across the 60 interventional studies, 194 across the 6 observational. Of the 57 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
4 of the studies in Diabetes Mellitus, Type 1 by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT06812988SanofiTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | 2027-04-29 |
| NCT07038473SanofiEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.
Enrolled participants will be followed for up to 10 years depending on the time the participants are included after initiating teplizumab treatment.
Patients diagnosed with Stage 2 T1D who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment. Approximately 1000 participants, in 85 sites across 19 countries will be enrolled over 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)
Exclusion Criteria -
(Note: Participants enrolled in other observational studies may be included.)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Teplizumab
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Time from teplizumab infusion start to the onset of Stage 3 T1D
Time frame: From start of infusion to maximum of 10 years
Proportion of participants who complete teplizumab treatment course
Time frame: Up to end of infusion, maximum of 5 years
Number of participants with adverse events during the infusion period
Time frame: Till 6 weeks post last infusion, maximum of 5 years
Number of participants with adverse events of special interest and serious adverse events
Time frame: From 6 weeks post last infusion through the follow-up, maximum of 10 years
Number of participants with T1D-related complications
Including but not limited to the following: diabetic ketoacidosis, severe hypoglycemia, retinopathy, nephropathy, neuropathy, cardiovascular events
Time frame: From infusion up to end of study, maximum of 10 years
Glycemic control assessment values
Time frame: From baseline through follow-up, maximum of 10 years
Change from baseline in glycated hemoglobin (HbA1c)
Time frame: From baseline through follow-up, maximum of 10 years
Proportion of participants achieving target HbA1c ≤ 6.5%
Time frame: From baseline through follow-up, maximum of 10 years
Proportion of participants using home glycemic control assessments (eg, SMBG, CGM)
Time frame: From baseline through follow-up, maximum of 10 years
Proportion of participants using glycemic control assessments in-clinic (eg, OGTT, FPG, MMTT, RPG)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time in range (TIR) (70 to 180 mg/dL [3.9 to 10 mmol/L])
CGM reading 70 to 180 mg/dL \[3.9 to 10 mmol/L\]
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time in tight range (TITR) (70 to 140 mg/dL [3.9 to 7.8 mmol/L])
CGM reading 70 to 140 mg/dL \[3.9 to 7.8 mmol/L\]
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time above tight range (TATR): >140 mg/dL (>7.8 mmol/L)
CGM reading \>140 mg/dL (\>7.8 mmol/L)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time above range (TAR): >180 mg/dL (>10 mmol/L)
CGM reading \>180 mg/dL (\>10 mmol/L)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time above range (TAR): >250 mg/dL (>13.9 mmol/L)
CGM reading \>250 mg/dL (\>13.9 mmol/L)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time below range (TBR): <70 mg/dL (<3.9 mmol/L)
CGM reading \<70 mg/dL (\<3.9 mmol/L)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in Time below range (TBR): <54 mg/dL (<3.0 mmol/L)
CGM reading \<54 mg/dL (\<3.0 mmol/L)
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in within-day glucose coefficient of variation
Time frame: From baseline through follow-up, maximum of 10 years
Mean change from baseline in between-day glucose coefficient of variation
Time frame: From baseline through follow-up, maximum of 10 years
Proportion of participants using insulin during the study period
Continuous subcutaneous insulin infusion, insulin pump, or pump integrated with an automated insulin delivery system
Time frame: Up to end of study, maximum of 10 years
Proportion of participants using other glucose lowering therapies during the study period
Time frame: Up to end of study, maximum of 10 years
Change in EuroQol 5-Dimensions (EQ-5D) scores in adult and pediatric participants
Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years
Change in Hospital Anxiety and Depression Scale (HADS) scores in adult participants
Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years
Change in World Health Organization-Five Well-Being Index (WHO-5) scores in pediatric participants
Time frame: From the first posttreatment visit after the last teplizumab infusion through follow-up, for a maximum of 10 years
Change in Diabetes Distress Scale (DDS) scores in adult participants
Time frame: From the time of Stage 3 T1D confirmation through follow-up, for a maximum of 10 years
Change in Hypoglycemia Fear Survey-II (HFS-II) scores in adult and pediatric participants
Time frame: From the time of Stage 3 T1D confirmation through follow-up, for a maximum of 10 years
Annualized rate of hospitalizations due to T1D related disease and complications
Time frame: Up to end of study, maximum of 10 years
Annualized rate of emergency room visits related to T1D related disease and complications
Time frame: Up to end of study, maximum of 10 years
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2035, 115 months after the start.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 115 months is above that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.